Drug intelligence / Profile preview

SSR180711C

Development stage: Discontinued
Lead developer: Sanofi
Modality: Small Molecules

Overview

SSR180711C is a small molecule drug developed as a selective partial agonist of the alpha-7 nicotinic acetylcholine receptor. It was investigated primarily for its potential to improve cognitive performance in patients with mild Alzheimer's disease. The drug acts by modulating cholinergic neurotransmission, which is implicated in cognitive processes. Clinical development included at least one Phase 2 trial, but this was terminated and there are no approved products or ongoing late-stage development known[1][2][3][4].

Other names: SSR-180711CSSR180711CSSR 180711C

Targets

CHRNA7 (α7 nicotinic receptor)

Beyond the preview

Go deeper on SSR180711C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SSR180711C.

Explore the full profile